Boehringer Ingelheim got the green light from the U.S. Food and Drug Administration (FDA) for JASCAYD (nerandomilast) tablets, allowing the addition of a new oral drug to the treatment modalities of adult patients
Suraksha Diagnostic, a prominent diagnostic chain located in Eastern India, held an informative scientific session on Advances in Genetics and Reproductive Health. The attendees heard from highly regarded experts from around the globe on the...
AbbVie received an approval from the U.S. Food and Drug Administration (FDA) to a supplemental new drug application (sNDA) for RINVOQ (upadacitinib).
Zen Multi-Specialty Hospital, Chembur, has been recognized by the Asia Book of Records for hosting a record-setting live laparoscopic surgery broadcast known as 'Laparoscopy Unlimited' with a total participation of 2635 medical professionals plus...
Bristol Myers Squibb (BMS) has made it clear that he is bringing Kopozgo (Mavacamten) to the Indian market. This is the first and only oral, selective cardiac myosin inhibitor for New York Heart Association (NYHA) Class II–III
Eli Lilly today announced it will present clinical data on Verzenio and multiple novel pipeline updates at the 2025 ESMO Annual Meeting in Berlin from October 17-21. The new data includes updates from across Lilly’s oncology portfolio as...
.png)
Max Healthcare is preparing for significant growth, and plans to spend more than ?5,000 crore in capital expenditure over the next three to four years, Managing Director Abhay Soi shared in an exclusive interview.The investment will be...
Samsung Biologics, a major global contract development and manufacturing organization (CDMO), has introduced ExellenS, a redesigned manufacturing framework
Merck, referred to as MSD outside the US and Canada, has declared that it will unveil the latest data concerning its pipeline for HIV treatment and prevention at the 20th European AIDS Conference
Novo Nordisk has announced they have entered into an agreement to acquire Akero Therapeutics. Akero Therapeutics is a clinical-stage biotechnology firm advancing therapies for serious metabolic diseases, for $5.2 billion. The acquisition...
.jpg)
, CDSCO.jpg)